A typical preparation of Francisella tularensis O-antigen yields a mixture of three types of saccharides.

Authors: Wang Q Shi X Leymarie N Madico G Sharon J Costello CE Zaia J
Address: Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts 02118, United States.
Journal:

Publication:

abstract

Tularemia is a severe infectious disease in humans caused by the Gram-negative bacterium Francisella tularensis (Ft). Because of its low infectious dose, high mortality rate, and the threat of its large-scale dissemination in weaponized form, development of vaccines and immunotherapeutics against Ft is essential. Ft lipopolysaccharide (LPS), which contains the linear graded-length saccharide component O-antigen (OAg) attached to a core oligosaccharide, has been reported as a protective antigen. Purification of LPS saccharides of defined length and composition is necessary to reveal the epitopes targeted by protective antibodies. In this study, we purified saccharides from LPS preparations from both the Ft subspecies holarctica live vaccine strain (LVS) and the virulent Ft subspecies tularensis SchuS4 strain using liquid chromatography. We then characterized the fractions using high-resolution mass spectrometry and tandem mass spectrometry. three types of saccharides were observed in both the LVS and SchuS4 preparations: two consisting of OAg tetrasaccharide repeats attached to one of two core oligosaccharide variants and one consisting of tetrasaccharide repeats only (coreless). The coreless OAg oligosaccharides were shown to contain Qui4NFm (4,6-dideoxy-4-formamido-D-glucose) at the nonreducing end and QuiNAc (2-acetamido-2,6-dideoxy-O-D-glucose) at the reducing end. Purified homogeneous preparations of saccharides of each type will allow mapping of protective epitopes in Ft LPS.

Related Articles
Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.
Hybridoma (Larchmt). 2011
Characterization of monoclonal antibodies to terminal and internal O-antigen epitopes of Francisella tularensis lipopolysaccharide.
Roche MI, Lu Z, Hui JH, Sharon J. Hybridoma (Larchmt). 2011 Feb; 30(1):19-28.
[Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].
Mol Gen Mikrobiol Virusol. 2000
[Species- and genus-specific antigenic epitopes of Francisella tularensis lipopolysaccharides].
Pavlovich NV, Aronova NV, Onoprienko NN, Sorokin VM, Mazrukho BL. Mol Gen Mikrobiol Virusol. 2000; (3):7-12.
Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.
PLoS One. 2010
Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis.
Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, Hunt JR, Imagawa S, Choudhury B, Inzana TJ, Maier TM, et al. PLoS One. 2010 Jul 6; 5(7):e11060. Epub 2010 Jul 6.
Review Virulence determinants and protective antigens of Francisella tularensis.
Curr Opin Microbiol. 2003
Review Virulence determinants and protective antigens of Francisella tularensis.
Sjöstedt A. Curr Opin Microbiol. 2003 Feb; 6(1):66-71.
Review Vaccination strategies for Francisella tularensis.
Adv Drug Deliv Rev. 2005
Review Vaccination strategies for Francisella tularensis.
Isherwood KE, Titball RW, Davies DH, Felgner PL, Morrow WJ. Adv Drug Deliv Rev. 2005 Jun 17; 57(9):1403-14.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.